Treatment of Parkinson’s disease psychosis

• Authors: Kevin J. BLACK
• Languages of publication: EN

Abstracts

EN

Early in the course of Parkinson disease (PD), treatment usually goes well. However, after five to ten years, things start to change as treatment requires higher doses of medications and side effects become more problematic. One of the most difficult problems is the development of hallucinations or delusions. Throughout the 20th century, treatment options were unproven and unsatisfactory, but the past 20 years have brought important changes. Two medications that are well tolerated in PD have now proved efficacious in randomized, controlled trials, and others are in development. Here I summarize this history briefly and provide a general plan for treating the patient with PD complicated by psychotic symptoms.

Keywords

EN

Antipsychotic Agents; Delirium; Delusions/therapy; Hallucinations/therapy; Parkinsonian Disorders; pimavanserin

• Publisher: ZOZ Ośrodek UMEA SHINODA-KURACEJO
• Journal: Medicina Internacia Revuo
• Year: 2017
• Volume: 28
• Issue: 109
• Pages: 266-271

Contributors

author

Kevin J. BLACK

• Washington University in Saint Louis School of Medicine: Saint Louis, MO, United States

References

• 1. Kehagia, A. A. Front Psychiatry 2016, 7, 110.
• 2. Kaiser, R.; Hofer, A.; Grapengiesser, A.; Gasser, T.; Kupsch, A.; Roots, I.; Brockmöller, J. Neurology 2003, 60 (11), 1750–1755.
• 3. Lin, J. J.; Yueh, K. C.; Lin, S. Z.; Harn, H. J.; Liu, J. T. J Neurol Sci 2007, 252 (2), 130–134.
• 4. Pascale, E.; Purcaro, C.; Passarelli, E.; Guglielmi, R.; Vestri, A. R.; Passarelli, F.; Meco, G. J Neurol Sci 2009, 276 (1-2), 18–21.
• 5. Factor, S. A.; Steenland, N. K.; Higgins, D. S.; Molho, E. S.; Kay, D. M.; Montimurro, J.; Rosen, A. R.; Zabetian, C. P.; Payami, H. Mov Disord 2011, 26 (12), 2190–2195.
• 6. Ravina, B.; Marder, K.; Fernandez, H. H.; Friedman, J. H.; McDonald, W.; Murphy, D.; Aarsland, D.; Babcock, D.; Cummings, J.; Endicott, J.; Factor, S.; Galpern, W.; Lees, A.; Marsh, L.; Stacy, M.; Gwinn-Hardy, K.; Voon, V.; Goetz, C. Mov Disord 2007, 22, 1061–1068.
• 7. Forsaa, E. B.; Larsen, J. P.; Wentzel-Larsen, T.; Goetz, C. G.; Stebbins, G. T.; Aarsland, D.; Alves, G. Arch Neurol 2010, 67, 996–1001.
• 8. Knysz III, W.; Coffey, C. E. In Guide to Neuropsychiatric Therapeutics; Coffey, C. E., McAllister, T. W., Silver, J. M., Eds.; Lippincott Williams & Wilkins: Philadelphia, PA, 2007; pp 14–23.
• 9. Parkinson Study Group. N Engl J Med 1999, 340, 757–763.
• 10. The French Clozapine Parkinson Study Group. Lancet 1999, 353, 2041–2042.
• 11. Factor, S. A.; Friedman, J. H.; Lannon, M. C.; Oakes, D.; Bourgeois, K. Mov Disord 2001, 16, 135–139.
• 12. Pollak, P.; Tison, F.; Rascol, O.; Destée, A.; Péré, J. J.; Senard, J. M.; Durif, F.; Bourdeix, I. J Neurol Neurosurg Psychiatry 2004, 75, 689–695.
• 13. Friedman, J. H.; Koller, W. C.; Lannon, M. C.; Busenbark, K.; Swanson-Hyland, E.; Smith, D. Neurology 1997, 48, 1077–1081.
• 14. Morgante, L.; Epifanio, A.; Spina, E.; Di Rosa, A. E.; Zappia, M.; Basile, G.; La Spina, P.; Quattrone, A. Neurol Sci 2002, 23 Suppl 2, S89–S90.
• 15. Factor, S. A.; Feustel, P. J.; Friedman, J. H.; Comella, C. L.; Goetz, C. G.; Kurlan, R.; Parsa, M.; Pfeiffer, R. Neurology 2003, 60, 1756–1761.
• 16. Alvir, J. M.; Lieberman, J. A.; Safferman, A. Z.; Schwimmer, J. L.; Schaaf, J. A. N Engl J Med 1993,329, 162–167.
• 17. Drew, L. Australas Psychiatry 2013, 21, 335–337.
• 18. Meltzer, H. Y.; Mills, R.; Revell, S.; Williams, H.; Johnson, A.; Bahr, D.; Friedman, J. H. Neuropsychopharmacology 2010, 35, 881–892.
• 19. Cummings, J.; Isaacson, S.; Mills, R.; Williams, H.; Chi-Burris, K.; Corbett, A.; Dhall, R.; Ballard, C. Lancet 2014, 383, 533–540.
• 20. Mills, R.; Friedman, J.; Ondo, W.; Pahwa, R.; Black, K.; Chi-Burris, K.; Williams, H. Parkinsonism Relat Disord 2016, 22 (Suppl 2), e92.
• 21. Friedman, J. H. Arch Intern Med 1985, 145, 913– 915.
• 22. Molho, E. S.; Factor, S. A. In Parkinson’s Disease and Nonmotor Dysfunction; Pfeiffer, R. F., Bodis- Wollner, I., Eds.; Current Clinical Neurology; Humana Press: Totowa, NJ, 2005; pp 49–74.
• 23. Stahl, S. M. In Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Application; Cambridge University Press: New York, 2013; pp 129–236.
• 24. Mendis, T.; Mohr, E.; George, A.; Rusk, I. N.; Gray, P.; Grimes, J. D. Mov Disord 1994, 9 (2), 197–200.
• 25. Lang, A. E.; Sandor, P.; Duff, J. Clin Neuropharmacol 1995, 18 (1), 39–45.
• 26. Sandor, P.; Lang, A. E.; Singal, S.; Angus, C. J Clin Psychopharmacol 1996, 16 (5), 395–399.
• 27. Arnold, G.; Trenkwalder, C.; Schwarz, J.; Oertel, W. H. Mov Disord 1994, 9 (2), 238–240.
• 28. Spieker, S.; Stetter, F.; Klockgether, T. Mov Disord 1995, 10 (6), 795–797.
• 29. Meco, G.; Alessandria, A.; Bonifati, V.; Giustini, P. Lancet 1994, 343 (8909), 1370–1371.
• 30. Workman Jr., R. H.; Orengo, C. A.; Bakey, A. A.; Molinari, V. A.; Kunik, M. E. J Neuropsychiatry Clin Neurosci 1997, 9, 594–597.
• 31. Mohr, E.; Mendis, T.; Hildebrand, K.; De Deyn, P. P. Mov Disord 2000, 15, 1230–1237.
• 32. Ford, B.; Lynch, T.; Greene, P. Lancet 1994, 344, 681.
• 33. Ellis, T.; Cudkowicz, M. E.; Sexton, P. M.; Growdon, J. H. J Neuropsychiatry Clin Neurosci 2000, 12, 364–369.
• 34. Breier, A.; Sutton, V. K.; Feldman, P. D.; Kadam, D. L.; Ferchland, I.; Wright, P.; Friedman, J. H. Biol Psychiatry 2002, 52, 438–445.
• 35. Ondo, W. G.; Levy, J. K.; Vuong, K. D.; Hunter, C.; Jankovic, J. Mov Disord 2002, 17, 1031–1305.
• 36. Goetz, C. G.; Blasucci, L. M.; Leurgans, S.; Pappert, E. J. Neurology 2000, 55, 789–794.
• 37. Nichols, M. J.; Hartlein, J. M.; Eicken, M. G.; Racette, B. A.; Black, K. J. F1000Res 2013, 2, 150.
• 38. López del Val, L. J.; Santos, S. Rev Neurol 2004, 39, 661–667.
• 39. Gómez-Esteban, J. C.; Zarranz, J. J.; Velasco, F.; Lezcano, E.; Lachen, M. C.; Rouco, I.; Barcena, J.; Boyero, S.; Ciordia, R.; Allue, I. Clin Neuropharmacol 2005, 28, 111–114.
• 40. Pintor, L.; Valldeoriola, F.; Baillés, E.; Martí, M. J.; Muñiz, A.; Tolosa, E. Clin Neuropharmacol 2012, 35, 61–66.
• 41. Schindehütte, J.; Trenkwalder, C. Clin Neurol Neurosurg 2007, 109, 188–191.
• 42. Friedman, J. H. Mov Disord 2012, 27, 803–804.
• 43. Fernandez, H. H.; Trieschmann, M. E.; Friedman, J. H. Clin Neuropharmacol 2004, 27, 4–5.
• 44. Friedman, J. H.; Berman, R. M.; Goetz, C. G.; Factor, S. A.; Ondo, W. G.; Wojcieszek, J.; Carson, W. H.; Marcus, R. N. Mov Disord 2006, 21, 2078– 2081.
• 45. Fernandez, H. H.; Okun, M. S.; Rodriguez, R. L.; Malaty, I. A.; Romrell, J.; Sun, A.; Wu, S. S.; Pillarisetty, S.; Nyathappa, A.; Eisenschenk, S. Int J Neurosci 2009, 119, 2196–2205.
• 46. Morgante, L.; Epifanio, A.; Spina, E.; Zappia, M.; Di Rosa, A. E.; Marconi, R.; Basile, G.; Di Raimondo, G.; La Spina, P.; Quattrone, A. Clin Neuropharmacol 2004, 27, 153–156.
• 47. Merims, D.; Balas, M.; Peretz, C.; Shabtai, H.; Giladi, N. Clin Neuropharmacol 2006, 29, 331–337.
• 48. Klein, C.; Prokhorov, T.; Miniovich, A.; Dobronevsky, E.; Rabey, J. M. Clin Neuropharmacol 2006, 29, 215–219.
• 49. Kurlan, R.; Cummings, J.; Raman, R.; Thal, L. Neurology 2007, 68, 1356–1363.
• 50. Shotbolt, P.; Samuel, M.; Fox, C.; David, A. S. Neuropsychiatr Dis Treat 2009, 5, 327–332.
• 51. Ondo, W. G.; Tintner, R.; Voung, K. D.; Lai, D.; Ringholz, G. Mov Disord 2005, 20, 958–963.
• 52. Prohorov, T.; Klein, C.; Miniovitz, A.; Dobronevsky, E.; Rabey, J. M. J Neurol 2006, 253, 171–175.
• 53. Rabey, J. M.; Prokhorov, T.; Miniovitz, A.; Dobronevsky, E.; Klein, C. Mov Disord 2007, 22, 313–318.
• 54. Goetz, C. G.; Diederich, N. J.; Fénelon, G. In Non-motor Symptoms of Parkinson’s Disease; Chaudhuri, K. R., Tolosa, E., Schapira, A. H. V., Poewe, W., Eds.; Oxford University Press, 2014; pp 184–208.
• 55. Rich, S. S.; Friedman, J. H. In Medical-Psychiatric Practice; American Psychiatric Press, 1995; Vol. 3, pp 151–182.
• 56. Gelfin, E.; Kaufman, Y.; Korn-Lubetzki, I.; Bloch, B.; Kremer, I.; Javitt, D. C.; Heresco-Levy, U. Int J Neuropsychopharmacol 2012, 15, 543–549.
• 57. Seppi, K.; Weintraub, D.; Coelho, M.; Perez-Lloret, S.; Fox, S. H.; Katzenschlager, R.; Hametner, E. M.; Poewe, W.; Rascol, O.; Goetz, C. G.; Sampaio, C.Mov Disord 2011, 26 Suppl 3, S42–S80.
• 58. Reading, P. J.; Luce, A. K.; McKeith, I. G. Mov Disord 2001, 16 (6), 1171–1174.
• 59. Burn, D.; Emre, M.; McKeith, I.; De Deyn, P. P.; Aarsland, D.; Hsu, C.; Lane, R. Mov Disord 2006, 21 (11), 1899–1907.
• 60. Sobow, T. Neurol Neurochir Pol 2007, 41 (3), 276–279.
• 61. Oh, Y. S.; Kim, J. S.; Lee, P. H. J Mov Disord 2015, 8 (2), 98–102.
• 62. Cummings, J.; Lai, T. J.; Hemrungrojn, S.; Mohandas, E.; Yun, K. S.; Nair, G.; Dash, A. CNS Neurosci Ther 2016, 22, 159–166.
• 63. Perez-Lloret, S.; Peralta, M. C.; Barrantes, F. J. Expert Opin Pharmacother 2016, 17, 2405–2415.
• 64. Ballard, C.; Brown, R.; Fossey, J.; Douglas, S.; Bradley, P.; Hancock, J.; James, I. A.; Juszczak, E.; Bentham, P.; Burns, A.; Lindesay, J.; Jacoby, R.; O’Brien, J.; Bullock, R.; Johnson, T.; Holmes, C.; Howard, R. Am J Geriatr Psychiatry 2009, 17, 726–733.
• 65. Black, K. J. Parkinson’s Link: Newsletter of the American Parkinson Disease Association Greater St. Louis Chapter 2016, 30 (3), 5,12. [Online]. Available at: http://works.bepress.com/kjb/64/ (accessed July 20, 2017)
• 66. Stacy, M.; Nasrallah, H.; Black, K. J.; Fredericks, D.; Isaacson, S.; Pahwa, R.; Stahl, S. “Parkinson’s disease psychosis: Considerations for switching from antipsychotics to pimavanserin,” submitted.

• Document Type: article